Shopping Cart
- Remove All
Your shopping cart is currently empty
[Pyr1]-Apelin-13
![[Pyr1]-Apelin-13](/group3/M00/35/70/CgoaEGayH1uEL2QFAAAAAJ1MIGI224.png)
[Pyr1]-Apelin-13 ([pGlu1]-Apelin-13) is a potent and selective endogenous Apelin receptor (APJ) agonist.
Catalog No. TP1260Cas No. 217082-60-5
Select Batch
Purity:100%
Contact us for more batch information
[Pyr1]-Apelin-13
Catalog No. TP1260Cas No. 217082-60-5
[Pyr1]-Apelin-13 ([pGlu1]-Apelin-13) is a potent and selective endogenous Apelin receptor (APJ) agonist.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $89 | In Stock | |
| 5 mg | $289 | In Stock | |
| 10 mg | $455 | In Stock | |
| 25 mg | $736 | In Stock | |
| 50 mg | $987 | In Stock | |
| 100 mg | $1,360 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "[Pyr1]-Apelin-13"
Azelaprag
T143902049980-18-7In house
Azelaprag (AMG 986) is an effective small-molecule apelin receptor agonist. Azelaprag can be used to treat neurological diseases and cardiovascular diseases.
- $396
Size
QTY
CMF019
T108431586787-08-7In house
CMF019 is a potent agonist of the Apelin receptor (APJ) with G protein bias. CMF019 binds to APJ (pKis: 8.58, 8.49, and 8.71 for the human, rat, and mouse).
- $122
Size
QTY
ELA-11 (human) acetate(1784687-32-6 free base)
TP1922L1
ELA-11 (human) acetate high affinity apelin receptor agonist (Ki = 14 nM). Bioactive fragment of ELA-32. Inhibits forskolin-induced cAMP production and stimulates β-arrestin recruitment in vitro.
- $133
Size
QTY
ELA-11 (human) acetate(1784687-32-6 free base)
TP1922L1
ELA-11 (human) acetate high affinity apelin receptor agonist (Ki = 14 nM). Bioactive fragment of ELA-32. Inhibits forskolin-induced cAMP production and stimulates β-arrestin recruitment in vitro.
- $133
Size
QTY
ELA-11 (human) acetate(1784687-32-6 free base)
TP1922L1
ELA-11 (human) acetate high affinity apelin receptor agonist (Ki = 14 nM). Bioactive fragment of ELA-32. Inhibits forskolin-induced cAMP production and stimulates β-arrestin recruitment in vitro.
- $133
Size
QTY
Apelin-12 acetate
T39823L
Apelin-12 acetate possesses a high affinity to orphan receptor APJ receptor. Apelin-12 acetate inhibits the JNK and p38 MAPK signaling pathway of the apoptosis-related MAPKs family, thus offering protection to neurons.
- $228
Size
QTY
Apelin-12 acetate
T39823L
Apelin-12 acetate possesses a high affinity to orphan receptor APJ receptor. Apelin-12 acetate inhibits the JNK and p38 MAPK signaling pathway of the apoptosis-related MAPKs family, thus offering protection to neurons.
- $228
Size
QTY
Apelin-12 acetate
T39823L
Apelin-12 acetate possesses a high affinity to orphan receptor APJ receptor. Apelin-12 acetate inhibits the JNK and p38 MAPK signaling pathway of the apoptosis-related MAPKs family, thus offering protection to neurons.
- $228
Size
QTY
Apelin-12 acetate
T39823L
Apelin-12 acetate possesses a high affinity to orphan receptor APJ receptor. Apelin-12 acetate inhibits the JNK and p38 MAPK signaling pathway of the apoptosis-related MAPKs family, thus offering protection to neurons.
- $228
Size
QTY
AM-8123
T394422049973-02-4In house
AM-8123 is an orally available nonpeptide APJ agonist.AM-8123 reduces collagen load and improves cardiac function. AM-8123 ameliorates myocardial infarction in rats and can be used to study cardiovascular diseases such as heart failure.
- $293
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | [Pyr1]-Apelin-13 ([pGlu1]-Apelin-13) is a potent and selective endogenous Apelin receptor (APJ) agonist. |
| In vitro | Encapsulation of [Pyr1]-apelin-13 in lipoPEG particles (lipoPEG-PA13) enables sustained and extended drug release in both in vitro and in vivo conditions[1]. |
| In vivo | In a study involving a mouse model of pressure-overload induced heart failure, nanocarriers containing [Pyr1]-apelin-13 demonstrated a prolonged effect in preventing cardiac dysfunction, highlighting its potential therapeutic benefits. Additionally, [Pyr1] apelin-13 at doses of 1 and 5 μg was found to enhance locomotor activity, alleviate pain symptoms, decrease cavity size, and reduce caspase-3 levels in rats, indicating its analgesic and anti-inflammatory properties. Furthermore, the compound significantly increased thermal paw withdrawal latency and, at a 5 μg dose, notably improved paw withdrawal threshold in comparison to spinal cord injury (SCI) animals from the second week post-SCI, suggesting its effectiveness in pain management and functional recovery post-SCI. |
| Alias | [pGlu1]-Apelin-13 |
| Molecular Weight | 1533.8 |
| Formula | C69H108N22O16S |
| Cas No. | 217082-60-5 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
| Solubility Information | H2O: 50 mg/mL (32.60 mM) | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
H2O
| ||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy [Pyr1]-Apelin-13 | purchase [Pyr1]-Apelin-13 | [Pyr1]-Apelin-13 cost | order [Pyr1]-Apelin-13 | [Pyr1]-Apelin-13 chemical structure | [Pyr1]-Apelin-13 in vivo | [Pyr1]-Apelin-13 in vitro | [Pyr1]-Apelin-13 formula | [Pyr1]-Apelin-13 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.